Want to see IL:SOFW full AI Analyst Report?
Top Page
Sofwave
(TASE:SOFW)
Select Model
Select Model
Rating:66Neutral
Price Target:
3,543.00
▼(-1.88% Downside)
Action:Reiterated
Date:09/25/26
Score is driven primarily by a strong financial turnaround (profitability and free cash flow improving alongside a very low-leverage balance sheet). Offsetting this, technical signals are mixed with negative MACD and the price still below the 100-day average, and valuation is relatively expensive at ~39x earnings with no dividend support.
Positive Factors
Profitability Inflection
The shift to positive operating and net profitability, while retaining a roughly 75% gross margin, indicates improving economic leverage in the business. If maintained, this earnings base can fund expansion internally and provide greater resilience than the prior loss-making periods.
Negative Factors
Prior Loss History
The recent profit improvement has not yet erased the evidence of a multi-year execution challenge. Earlier operating and net losses show that attractive gross margins alone did not ensure profitability, so sustaining the current cost structure remains important to the investment case.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Inflection
The shift to positive operating and net profitability, while retaining a roughly 75% gross margin, indicates improving economic leverage in the business. If maintained, this earnings base can fund expansion internally and provide greater resilience than the prior loss-making periods.
Read all positive factors
Sofwave (SOFW) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪1.25B
Dividend YieldN/A
Average Volume (3M)99.11K
Price to Earnings (P/E)44.4
Beta (1Y)0.62
Revenue Growth30.12%
EPS GrowthN/A
CountryIL
Employees151
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.25
Shares Outstanding36,374,622
10 Day Avg. Volume183,103
30 Day Avg. Volume99,107
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)9.34
Price to Sales (P/S)3.22
P/FCF Ratio21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sofwave Business Overview & Revenue Model
Company Description
Founded in 2015, Sofwave Medical Ltd. is an Israeli company dedicated to developing cutting-edge ultrasound technology. This technology is employed for the non-invasive treatment of fine lines and wrinkles, with the company's reach extending to ph...
How the Company Makes Money
Sofwave primarily makes money by selling and deploying its ultrasound-based aesthetic treatment systems to medical professionals (e.g., dermatology, plastic surgery, and aesthetic clinics). Revenue is generated from (1) capital equipment sales of ...
Sofwave Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 104.85M | 94.86M | 59.65M | 50.31M | 35.63M | 21.84M |
| Gross Profit | 78.97M | 70.27M | 45.34M | 37.48M | 26.33M | 16.24M |
| EBITDA | 12.28M | 9.39M | -2.19M | -6.61M | -17.55M | -6.43M |
| Net Income | 8.92M | 5.94M | -4.55M | -8.28M | -19.53M | -6.83M |
Balance Sheet | ||||||
| Total Assets | 61.72M | 55.78M | 43.03M | 43.54M | 46.08M | 60.77M |
| Cash, Cash Equivalents and Short-Term Investments | 38.57M | 35.28M | 21.62M | 24.42M | 32.01M | 46.22M |
| Total Debt | 1.42M | 1.12M | 1.40M | 1.33M | 1.92M | 2.37M |
| Total Liabilities | 23.95M | 23.06M | 18.50M | 17.19M | 13.74M | 14.07M |
| Stockholders Equity | 37.77M | 32.72M | 24.53M | 26.34M | 32.34M | 46.70M |
Cash Flow | ||||||
| Free Cash Flow | 14.81M | 14.51M | -2.67M | -6.71M | -11.14M | -2.92M |
| Operating Cash Flow | 15.61M | 15.08M | -2.40M | -6.31M | -10.69M | -2.10M |
| Investing Cash Flow | -10.98M | -1.15M | 254.00K | 409.00K | -260.00K | -982.00K |
| Financing Cash Flow | 20.23K | -469.79K | -620.00K | -1.72M | -1.35M | 46.64M |
Sofwave Technical Analysis
Neutral
3611.00
Price Trends
3663.04
Negative
3962.20
Negative
3749.78
Negative
Market Momentum
-77.26
Negative
52.89
Neutral
56.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:SOFW, the sentiment is Neutral. The current price of 3611 is above the 20-day moving average (MA) of 3386.15, below the 50-day MA of 3663.04, and below the 200-day MA of 3749.78, indicating a neutral trend. The MACD of -77.26 indicates Negative momentum. The RSI at 52.89 is Neutral, neither overbought nor oversold. The STOCH value of 56.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:SOFW.
Sofwave Peers Comparison
UnderperformOutperform
Sector (55)
IL:SOFW
Sofwave
3,546.00
847.00
31.38%
IL:BWAY
Brainsway
4,051.00
1,479.00
57.50%
IL:ILX
Ilex Medical
5,155.00
-1,018.28
-16.49%
IL:ALMD
Allmed Solution
32.50
-1.20
-3.56%
IL:EPIT
Epitomee Med
405.00
-381.20
-48.49%
IL:PLSM
Pulsenmore
717.60
-3,041.52
-80.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.